Elite Pharma Stock Book Value Per Share
| ELTPDelisted Stock | USD 0.04 0 6.75% |
Elite Pharma fundamentals help investors to digest information that contributes to Elite Pharma's financial success or failures. It also enables traders to predict the movement of Elite OTC Stock. The fundamental analysis module provides a way to measure Elite Pharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Elite Pharma otc stock.
Elite |
Elite Pharma OTC Stock Book Value Per Share Analysis
Elite Pharma's Book Value per Share (B/S) can be calculated by subtracting liabilities from assets, and then dividing it by the total number of currently outstanding shares. It indicates the level of safety associated with each common share after removing the effects of liabilities. In other words, a shareholder can use this ratio to see how much he or she can sell the stake in the company in the event of a liquidation.
More About Book Value Per Share | All Equity Analysis
Book Value per Share | = | Common EquityAverage Shares |
Current Elite Pharma Book Value Per Share | 0.03 X |
Most of Elite Pharma's fundamental indicators, such as Book Value Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Elite Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The naive approach to look at Book Value per Share is to compare it to current stock price. If Book Value per Share is higher than the currently traded stock price, the company can be considered undervalued. However, investors must be aware that conventional calculation of Book Value does not include intangible assets such as goodwill, intellectual property, trademarks or brands and may not be an appropriate measure for many firms.
CompetitionIn accordance with the recently published financial statements, the book value per share of Elite Pharma is about 0.027 times. This is 101.59% lower than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The book value per share for all United States stocks is 100.0% higher than that of the company.
Elite Book Value Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Elite Pharma's direct or indirect competition against its Book Value Per Share to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Elite Pharma could also be used in its relative valuation, which is a method of valuing Elite Pharma by comparing valuation metrics of similar companies.Elite Pharma is currently under evaluation in book value per share category among its peers.
Elite Fundamentals
| Return On Equity | 0.27 | ||||
| Return On Asset | 0.0739 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | 0.15 % | ||||
| Current Valuation | 27.92 M | ||||
| Shares Outstanding | 1.01 B | ||||
| Shares Owned By Insiders | 17.53 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Number Of Shares Shorted | 757.07 K | ||||
| Price To Earning | 5.21 X | ||||
| Price To Book | 1.12 X | ||||
| Price To Sales | 0.92 X | ||||
| Revenue | 32.26 M | ||||
| Gross Profit | 14.8 M | ||||
| EBITDA | 7.93 M | ||||
| Net Income | 8.9 M | ||||
| Cash And Equivalents | 19.78 M | ||||
| Cash Per Share | 0.02 X | ||||
| Total Debt | 1.39 M | ||||
| Debt To Equity | 0.57 % | ||||
| Current Ratio | 4.50 X | ||||
| Book Value Per Share | 0.03 X | ||||
| Cash Flow From Operations | 6.51 M | ||||
| Short Ratio | 0.87 X | ||||
| Earnings Per Share | 0.01 X | ||||
| Target Price | 4.0 | ||||
| Number Of Employees | 43 | ||||
| Beta | 0.29 | ||||
| Market Capitalization | 38.53 M | ||||
| Total Asset | 35.15 M | ||||
| Retained Earnings | (147.41 M) | ||||
| Working Capital | 14.53 M | ||||
| Current Asset | 19.66 M | ||||
| Current Liabilities | 5.13 M | ||||
| Z Score | 10.6 | ||||
| Net Asset | 35.15 M |
About Elite Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Elite Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Elite Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Elite Pharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Elite Pharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Elite Pharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Elite Pharma will appreciate offsetting losses from the drop in the long position's value.Moving against Elite OTC Stock
| 0.68 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.67 | DYNT | Dynatronics | PairCorr |
| 0.63 | SXTC | China SXT Pharmaceuticals | PairCorr |
| 0.58 | BGXX | Bright Green Corp | PairCorr |
| 0.57 | RMTI | Rockwell Medical | PairCorr |
The ability to find closely correlated positions to Elite Pharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Elite Pharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Elite Pharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Elite Pharma to buy it.
The correlation of Elite Pharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Elite Pharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Elite Pharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Elite Pharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Other Consideration for investing in Elite OTC Stock
If you are still planning to invest in Elite Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Elite Pharma's history and understand the potential risks before investing.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Global Correlations Find global opportunities by holding instruments from different markets |